Search filters
Filters
Clear All

Phase

  • 4
  • 4
  • 4
  • 4

Found 4 Vision Loss trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 31420: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stag

99 years and younger
All genders
This is a double-blind, randomized, multicenter international Phase 3 study of CAEL-101 combined with standard of care plasma cell dyscrasia (PCD) treatment versus placebo combined with standard of care PCD treatment in Mayo stage IIIa PCD treatment-naïve AL amyloidosis patients. T
Learn More

OCEANIC

99 years and younger
All genders
OCEANIC-STROKE (study 20604) is a multicenter, international, randomized, placebo controlled, double-blind, parallel group, event driven phase 3 study. The purpose of this study is to investigate the efficacy of the oral FXIa inhibitor asundexian in prevention of ischemic stroke and its safety (bleeding) compared with placebo on top of background …
Learn More

A phase 3, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia

99 years and younger
All genders
To demonstrate that the addition of ianalumab to standard first-line corticosteroids prolongs Time to Treatment Failure compared to Corticosteroids alone in participants with primary ITP. ITP means immune thrombocytopenia. Time from randomization to treatment failure which is defined as Platelet count below 30G/L after 8 weeks from randomization. Need for …
Learn More

UPCC 15120: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastat

99 years and younger
All genders
The purpose of this study is to find out if capivasertib given with paclitaxel is an effective treatment for triple negative breast cancer (TNBC). As part of this study subjects will receive paclitaxel in combination with either capivasertib or a placebo. Eligible subjects will be those diagnosed with metastatic (or …
Learn More